摘要
目的:探究心脉隆注射液对高龄急性心肌梗死(AMI)心力衰竭患者心脏及血管内皮功能的影响。方法:选择2015年3月~2017年7月在我院诊治的122例高龄AMI心力衰竭患者,患者被随机均分成常规治疗组和心脉隆组(在常规治疗组基础上接受心脉隆注射液),疗程10d,随访6个月。分别观察两组治疗前后LVEF、测定室壁运动积分(WMSI)、血清脑钠肽(BNP)、hsCRP、cTnI、一氧化氮(NO)、内皮素-1(ET-1)水平及肱动脉血管内径变化。结果:与治疗前比较,治疗后两组患者的LVEF[常规治疗组:(35.42±5.11)%比(44.62±5.88)%;心脉隆组:(36.13±5.64)%比(49.75±6.18)%]均显著升高,且心脉隆组显著高于常规治疗组,WMSI评分[常规治疗组:(2.49±0.51)分比(1.45±0.34)分;心脉隆组:(2.51±0.42)分比(1.12±0.27)分]及NYHA心功能分级(常规治疗组:3.19±0.44 比 2.65±0.36;心脉隆组:3.21±0.42 比 2.11±0.28)则均显著降低,且心脉隆组显著低于常规治疗组(P均=0.001);治疗后两组患者的血清BNP[常规治疗组:(986.72±245.63)pg/ml 比(764.42±217.33)pg/ml;心脉隆组:(989.99±243.54)pg/ml 比(607.82±198.65)pg/ml]、hsCRP[常规治疗组:(24.31±3.82)mg/L 比(14.52±1.69)mg/L;心脉隆组:(24.93±3.74)mg/L 比(7.81±0.96)mg/L]、cTnI[常规治疗组:(5.29±0.43)μg/L比(3.01±0.27)μg/L;心脉隆组:(5.37±0.64)μg/L比(1.42±0.33)μg/L ]、ET-1[常规治疗组:(95.67±16.32)ng/L比(76.34±17.82)ng/L;心脉隆组:(96.13±17.21)ng/L比(57.29±14.63)ng/L]水平均显著下降,且心脉隆组降低更显著,而血清NO水平[常规治疗组:(108.35±21.67)μmol/L比(129.68±25.83)μmol/L;心脉隆组:(110.26±22.71)μmol/L 比(156.82±24.19)μmol/L]则均显著升高,且心脉隆升高更显著( P 均=0.001);治疗后,心脉隆组的反应性充血肱动脉内径(D 充血)、肱动脉内皮依赖性舒张功能(FMD)均显著升高且显著高于常规治疗组( P <0.05或<0.01)。结论:心脉隆注射液能够显著改善AMI心力衰竭患者心功能和血管内皮功能
Objective: To explore influence of Xinmailong injection on cardiac function and vascular endothelial function in advanced aged patients with acute myocardial infarction (AMI) heart failure (HF). Methods: A total of 122 advanced aged AMI-HF patients treated in our hospital from Mar 2015 to Jul 2017 were selected, randomly and equally divided into routine treatment group (received routine anti-HF medication) and Xinmailong group (received Xinmailong injection based on routine treatment group), both groups were treated for 10d and then followed up for six months.LVEF, wall motion score index (WMSI), serum levels of BNP,hsCRP,cTnI, nitric oxide (NO), endothelin (ET)-1 and inner diameter of brachial artery were observed and compared between two groups before and after treatment. Results: Compared with before treatment, there were significant rise in LVEF[routine treatment group:(35.42±5.11)% vs.(44.62±5.88)%;Xinmailong group:(36.13±5.64)% vs.(49.75±6.18)%] and serum NO level[routine treatmentgroup:(108.35±21.67)μmol/L vs.(129.68±25.83)μmol/L;Xinmailong group:(110.26±22.71)μmol/L vs.(156.82±24.19)μmol/L], and significant reductions in WMSI[routine treatment group:(2.49±0.51)score vs.(1.45±0.34)score;Xinmailong group:(2.51±0.42)score vs.(1.12±0.27)score], NYHA class(routine treatment group: 3.19±0.44 vs. 2.65±0.36;Xinmailong group: 3.21±0.42 vs. 2.11±0.28), serum levels of BNP[routine treatment group:(986.72±245.63)pg/ml vs.(764.42±217.33)pg/ml;Xinmailong group:(989.99±243.54)pg/ml vs.(607.82±198.65)pg/ml], hsCRP[routine treatment group:(24.31±3.82)mg/L vs.(14.52±1.69)mg/L;Xinmailong group:(24.93±3.74)mg/L vs.(7.81±0.96)mg/L], cTnI [routine treatment group:(5.29±0.43)μg/L vs.(3.01±0.27)μg/L;Xinmailong group:(5.37±0.64)μg/L vs.(1.42±0.33)μg/L ]and ET-1[routine treatment group:(95.67±16.32)ng/L vs.(76.34±17.82)ng/L;Xinmailong group:(96.13±17.21)ng/L vs.(57.29±14.63)ng/L] in two groups;and LVEF and serum NO level of Xinmailong group were significantly higher than those of routine tre
作者
闫茹玉
孙秋月
刘青敏
YAN Ru-yu;SUN Qiu-yue;LIU Qing-min(Second Department of Internal Medicine,Traditional Chinese Medicine Hospital of Hengshui City,Hengshui,Hebei,053000,China)
出处
《心血管康复医学杂志》
CAS
2019年第4期473-477,共5页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
心肌梗死
心力衰竭
老年人
Myocardial infarction
Heart failure
Aged
